Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer

Kijanka, Gregor; Hector, Suzanne; Kay, Elaine W.; Murray, Frank E.; Cummins, Robert; Murphy, Derek; MacCraith, Brian D.; Prehn, Jochen H.M.; Kenny, Dermot

doi:10.1136/gut.2009.178574

Cited by 63 publications

(81 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with previous reports (26,27), we found that TCF3 is overexpressed in colon cancer tissues compared with adjacent noncancerous tissues. It has also been reported that TCF3 is highly expressed in various cancers, including prostate, gastric, and renal cancers (28)(29)(30).…”

Section: Discussionsupporting

confidence: 93%

“…The bHLH family member E12/E47 participates in the repression of E-cadherin expression and induction of the epithelial-to-mesenchymal transition, leading to the acquisition of invasive properties (24,25). Moreover, TCF3/E2A is overexpressed in colon cancer (26,27), prostate cancer (28,29), and renal cancer (30) and plays a critical role in the proliferation and survival of tumor cells (29). Consistent with these reports, we found that TCF3 was highly expressed in colon cancer tissues compared with the noncancerous tissues (Fig.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

ASBEL –TCF3 complex is required for the tumorigenicity of colorectal cancer cells

Taniue

Kurimoto

Takeda

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Wnt/β-catenin signaling plays a key role in the tumorigenicity of colon cancer. Furthermore, it has been reported that lncRNAs are dysregulated in several steps of cancer development. Here we show that β-catenin directly activates the transcription of the long noncoding RNA (lncRNA) ASBEL [antisense ncRNA in the ANA (Abundant in neuroepithelium area)/BTG3 (B-cell translocation gene 3) locus] and transcription factor 3 (TCF3), both of which are required for the survival and tumorigenicity of colorectal cancer cells. ASBEL interacts with and recruits TCF3 to the activating transcription factor 3 (ATF3) locus, where it represses the expression of ATF3. Furthermore, we demonstrate that ASBEL-TCF3-mediated down-regulation of ATF3 expression is required for the proliferation and tumorigenicity of colon tumor cells. ATF3, in turn, represses the expression of ASBEL. Our results reveal a pathway involving an lncRNA and two transcription factors that plays a key role in Wnt/β-catenin-mediated tumorigenesis. These results may provide insights into the variety of biological and pathological processes regulated by Wnt/β-catenin signaling.β-catenin | noncoding RNA | ASBEL | colorectal tumorigenesis | ATF3

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Resultsmentioning

confidence: 99%

ASBEL –TCF3 complex is required for the tumorigenicity of colorectal cancer cells

Taniue

Kurimoto

Takeda

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…In the subjects with CEA level below 5 ng/mL, the classifier had a strong power in discriminating the CRC patients and the healthy controls, with an AUC of 0.975, indicating that the classifier might be able to fill in gaps of CEA in diagnosing early CRC. The classifier also has a higher validity than the reported arrays of some known CRC-associated antigens for the detection of CRC (21)(22)(23). Furthermore, OR for cases with the classification score more than 0.50 being associated with CRC was 99.0, which was much higher than an OR of 7.6 for G-FOBT and an OR of 18.7 for serum miR-92, the two methods recently reported for the early detection of CRC (28,29).…”

Section: Discussionmentioning

confidence: 99%

“…Profiling of circulating autoantibodies is therefore very attractive in diagnosing cancers at early stage. With the use of SEREX, protein array, and ELISA, autoantibodies to TAAs have been found in sera of the patients with CRC (14,(21)(22)(23). Although a panel of phage peptides developed by SEREX has high sensitivity and specificity in discriminating colon cancer patients with healthy controls, TAAs have not been fully identified (14).…”

Section: Introductionmentioning

confidence: 99%

Development of Autoantibody Signatures as Biomarkers for Early Detection of Colorectal Carcinoma

Chang

Wu²,

Cao³

et al. 2011

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To select autoantibody signatures for early detection of colorectal cancer (CRC). Experimental Design: A phage cDNA expression library was constructed with fresh tumors from 30 CRC patients and biopanned by using serum pools of 20 CRC patients and 20 healthy controls. A classifier was discovered in the training set of 30 CRC patients at stages I and II and 30 matched healthy controls and then blindly validated in an independent set of 60 CRC patients, 60 healthy controls, 52 polyps patients, and 30 autoimmune diseases patients. Expression of proteins was examined by using immunohistochemistry.Results: Five-phage peptide clones showing higher discriminatory power than others in training set were selected for validation. The five-phage peptide classifier was able to discriminate between early CRC patients and healthy controls, with sensitivities of 90.0% to 92.7% and specificities of 91.7% to 93.3%. In those with serum carcinoembryonic antigen less than 5 ng/mL, the classifier was efficient in discriminating CRC from healthy controls, with an area under the curve of 0.975. The classifier was able to discriminate all of the 9 patients with serrated adenoma from healthy controls. Thirteen (43.3%) of the patients with autoimmune diseases were misclassified. Of the five phage peptides, one encoded a peptide identical to immunoglobulin G (IgG) heavy-chain constant region. IgG immunostaining was stronger in mesenchymal cells than in cancer cells in the tumors and was apparent in serrated adenoma.Conclusions: The five-phage peptide classifier stands out as promising early diagnostic biomarkers for CRC, but it is unsuitable for discriminating CRC from autoimmune diseases. Truncated IgGs generated from the tumors might be novel CRC-associated antigens. Clin Cancer Res; 17(17); 5715-24. Ó2011 AACR.

show abstract

“…TRIM21 also targets other factors that are responsible for type-I IFN activation, including IRF-5, IRF-7 and IRF-8, for degradation through proteasomal or, thus far, unknown mechanisms (Higgs et al, 2008(Higgs et al, , 2010Espinosa et al, 2009;Yoshimi et al, 2009;Young et al, 2011;Lazzari et al, 2014). TRIMs are often described as autoantigens in autoimmune diseases and cancers, including TRIM21 and TRIM68 in SLE and Sjögren syndrome (Der et al, 1998;Billaut-Mulot et al, 2001), TRIM33 in dermatomyositis and the associated paraneoplastic phenomena (Targoff et al, 2006;Fujimoto et al, 2012), TRIM19 in primary biliary cirrhosis (Stinton et al, 2011), and TRIM28 in colon cancer (Kijanka et al, 2010;Hector et al, 2012) and dermatomyositis (Satoh et al, 2012). Furthermore, TRIMs as a protein family have been associated with the regulation of type-I IFN responses (Versteeg et al, 2013), in keeping with relationships described for TRIM21 above .…”

Section: Role Of Trim-directed Precision Autophagy In Diseasementioning

confidence: 99%

Precision autophagy directed by receptor regulators – emerging examples within the TRIM family

Kimura

Mandell

Deretić

2016

Journal of Cell Science

View full text Add to dashboard Cite

Selective autophagy entails cooperation between target recognition and assembly of the autophagic apparatus. Target recognition is conducted by receptors that often recognize tags, such as ubiquitin and galectins, although examples of selective autophagy independent of these tags are emerging. It is less known how receptors cooperate with the upstream autophagic regulators, beyond the well-characterized association of receptors with Atg8 or its homologs, such as LC3B (encoded by MAP1LC3B), on autophagic membranes. The molecular details of the emerging role in autophagy of the family of proteins called TRIMs shed light on the coordination between cargo recognition and the assembly and activation of the principal autophagy regulators. In their autophagy roles, TRIMs act both as receptors and as platforms ('receptor regulators') for the assembly of the core autophagy regulators, such as ULK1 and Beclin 1 in their activated state. As autophagic receptors, TRIMs can directly recognize endogenous or exogenous targets, obviating a need for intermediary autophagic tags, such as ubiquitin and galectins. The receptor and regulatory features embodied within the same entity allow TRIMs to govern cargo degradation in a highly exact process termed 'precision autophagy'.

show abstract

Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer

Abstract: IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer. Gut 2010;59:69-78.

Cited by 63 publications

References 54 publications

ASBEL –TCF3 complex is required for the tumorigenicity of colorectal cancer cells

ASBEL –TCF3 complex is required for the tumorigenicity of colorectal cancer cells

Development of Autoantibody Signatures as Biomarkers for Early Detection of Colorectal Carcinoma

Precision autophagy directed by receptor regulators – emerging examples within the TRIM family

Contact Info

Product

Resources

About